Welcome to our dedicated page for Biocardia news (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on Biocardia stock.
BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its recurring company updates center on the CardiAMP autologous cell therapy platform, CardiALLO allogeneic cell therapy programs, and device and software technologies used to deliver therapies to the heart, including the Helix transendocardial delivery catheter and Heart3D Fusion Imaging software.
News about BCDA commonly covers clinical results in ischemic heart failure with reduced ejection fraction, FDA and Japan PMDA regulatory interactions, patent protection for procedure-planning and navigation technology, and annual financial results. Company communications also address the role of Helix and related vascular navigation platforms in minimally invasive intramyocardial delivery of therapeutic and diagnostic agents.
BioCardia, Inc. (Nasdaq: BCDA) will join the Russell Microcap Index, effective June 28, 2021, following the annual reconstitution of the Russell Indexes. This inclusion is expected to attract more investors and enhance liquidity. Russell Indexes are a significant reference for approximately $10.6 trillion in assets, making this a notable milestone for BioCardia. The membership will last for one year and will automatically include the company in relevant growth and value style indexes, provided by FTSE Russell.
BioCardia, Inc. (Nasdaq: BCDA) announced that CEO Peter Altman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10. His presentation is scheduled for June 8 at 4:30 PM ET on Track 3. Investors can register to watch the presentation online. BioCardia is focused on developing regenerative biologic therapies for cardiovascular and pulmonary diseases, with key products like CardiAMP™ cell therapies and various delivery systems.
BioCardia, Inc. (Nasdaq: BCDA) reported its Q1 2021 financial results, highlighting key advancements in its CardiAMP autologous and allogeneic cell therapy pipelines. The CardiAMP trials (BCDA-01 and BCDA-02) are progressing with 94 patients enrolled and FDA crossover approvals. Financially, the net loss decreased to $3.0 million from $4.6 million YoY, with R&D expenses down 34% to $1.8 million. The company also engaged in a $20 million equity line, selling $2 million in common stock. Upcoming milestones include a DSMB review on June 22, 2021, and additional patient enrollments.
BioCardia has announced a collaboration with a leading Japanese biotechnology company regarding its Helix catheter biotherapeutic delivery products. The agreement, valued at $500,000, spans one year and includes options for a non-exclusive worldwide license for certain cardiac cell types. CEO Peter Altman emphasized the significance of their Helix technology, which has shown superior efficiency and clinical performance in recent studies. This partnership represents a strategic advancement, aiming for clinical development and commercialization of biotherapeutic products targeting heart conditions.
BioCardia, Inc. (Nasdaq: BCDA) reported Q4 and full-year financial results for 2020, with a significant revenue drop to $145,000 from $710,000 in 2019 due to lower partnership activities and reduced catheter sales. The company closed a $19 million financing and a $20 million equity line in Q4. The CardiAMP™ Heart Failure Trial received positive DSMB recommendations, indicating no safety concerns. Upcoming milestones include the Phase III CardiAMP Chronic Myocardial Ischemia trial. The net loss for 2020 was $15 million, a slight increase from the previous year.
BioCardia (Nasdaq: BCDA) announces CEO Dr. Peter Altman will present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference, scheduled for March 17-19, 2021. Dr. Altman's live fireside chat is set for 3:30 PM ET on March 19. Registered attendees can also access a corporate presentation on the conference website and request a 1x1 meeting with Dr. Altman post-conference. BioCardia focuses on developing regenerative therapies for cardiovascular disease, with notable products like the CardiAMP cell therapy and the Helix Biotherapeutic Delivery System.
BioCardia, Inc. (Nasdaq: BCDA) announced an agreement with a leading Japanese pharmaceutical company for the Helix catheter biotherapeutic delivery system. The deal includes a $500,000 upfront payment, partially applicable to products and services. This one-year agreement allows for negotiation of a non-exclusive worldwide license for specific cardiac-related cell types. CEO Peter Altman emphasized the Helix system's unique position in the market and its efficiency in delivering therapies, which supports ongoing clinical developments in heart failure treatments.
BioCardia, Inc. (Nasdaq: BCDA) announced leadership changes in its clinical team, effective February 15, 2021. Dr. Sujith Shetty has been appointed as Chief Medical Officer, succeeding Dr. Eric Duckers, who resigned to explore new opportunities but will remain as a consultant. Ms. Debby Holmes-Higgin retains her position as Vice President of Clinical with broader responsibilities. The changes follow a successful Data Safety Monitoring Board Review of the CardiAMP Heart Failure Trial, aimed at enhancing the trial's success.
BioCardia, Inc. (Nasdaq: BCDA) announced the election of Krisztina Zsebo, Ph.D., to its Board of Directors during the 2020 Annual Meeting of Stockholders. With over 30 years in biotech, Dr. Zsebo has raised more than $200 million and launched products generating over $3.5 billion in annual sales. She replaces Fernando L. Fernandez, who completed his term. Dr. Zsebo is expected to chair the Science and Technology Committee, enhancing BioCardia's product development initiatives. The company focuses on regenerative therapies for cardiovascular and respiratory diseases.
BioCardia, Inc. (Nasdaq: BCDA) has announced the issuance of U.S. Patent No. 10,874,831 for a new device designed to enhance the delivery of biotherapeutics in cardiovascular treatments. This technology is expected to improve physician control during procedures involving complex vascular anatomy. The patented design is incorporated in the company’s recently approved products, Morph DNA and AVANCE steerable catheters, which could bolster clinical programs for heart failure and chronic ischemia. CEO Peter Altman emphasizes the importance of delivery systems in therapeutic success.